Current Oncology Reports

, Volume 7, Issue 5, pp 349–356 | Cite as

Linking KSHV to human cancer

  • Emily L. Wong
  • Blossom Damania


Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), has been linked to several malignancies in humans. KSHV is the etiologic agent associated with the development of Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman’s disease (MCD). KSHV is a double-stranded DNA virus that has been classified as a gammaherpesvirus. Here, we review the association of KSHV with human cancer, viral genes that may potentially be involved in the neoplastic process, and current therapies used to treat KS, PEL, and MCD.


Primary Effusion Lymphoma KSHV Infection Primary Effusion Lymphoma Cell KSHV vGPCR Stabilize Cytokine mRNAs 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kaposi M: Idiopatisches multiples Pigmentsarkom der Haut. Arch Dermatol Syphillis 1872, 4:265–273.CrossRefGoogle Scholar
  2. 2.
    Chang Y, Cesarman E, Pessin MS, et al.: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994, 266:1865–1869. Paper identifying the presence of Kaposi’s sarcoma-associated herpesvirus (KSHV) in Kaposi’s sarcoma lesions.PubMedCrossRefGoogle Scholar
  3. 3.
    Martin JN, Ganem DE, Osmond DH, et al.: Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998, 338:948–954.PubMedCrossRefGoogle Scholar
  4. 4.
    Friedman-Kien AE: Disseminated Kaposi’s sarcoma syndrome in young homosexual men. J Am Acad Dermatol 1981, 5:468–471.PubMedCrossRefGoogle Scholar
  5. 5.
    Civati G, Busnach G, Brando B, et al.: Occurrence of Kaposi’s sarcoma in renal transplant recipients treated with low doses of cyclosporine. Transplant Proc 1988, 20:924–928.PubMedGoogle Scholar
  6. 6.
    Antman K, Chang Y: Kaposi’s sarcoma. N Engl J Med 2000, 342:1027–1038.PubMedCrossRefGoogle Scholar
  7. 7.
    Dupin N, Grandadam M, Calvez V, et al.: Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi’s sarcoma. Lancet 1995, 345:761–762.PubMedCrossRefGoogle Scholar
  8. 8.
    Hong YK, Foreman K, Shin JW, et al.: Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcomaassociated herpesvirus. Nat Genet 2004, 36:683–685.PubMedCrossRefGoogle Scholar
  9. 9.
    Kaaya SF, Leshabari MT, Mbwambo JK: Risk behaviors and vulnerability to HIV infection among Tanzanian youth. J Health Popul Dev Ctries 1998, 1:51–60.PubMedGoogle Scholar
  10. 10.
    Rabkin CS, Janz S, Lash A, et al.: Monoclonal origin of multicentric Kaposi’s sarcoma lesions. N Engl J Med 1997, 336:988–993.PubMedCrossRefGoogle Scholar
  11. 11.
    Harwood AR, Osoba D, Hofstader SL, et al.: Kaposi’s sarcoma in recipients of renal transplants. Am J Med 1979, 67:759–765.PubMedCrossRefGoogle Scholar
  12. 12.
    De Rosa G, Barra E, Guarino M, et al.: Multicentric Castleman’s disease in association with Kaposi’s sarcoma. Appl Pathol 1989, 7:105–110.PubMedGoogle Scholar
  13. 13.
    Farge D, Lebbe C, Marjanovic Z, et al.: Human herpes virus-8 and other risk factors for Kaposi’s sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d’ Ile de France (GCIF). Transplantation 1999, 67:1236–1242.PubMedCrossRefGoogle Scholar
  14. 14.
    Barozzi P, Luppi M, Facchetti F, et al.: Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 2003, 9:554–561.PubMedCrossRefGoogle Scholar
  15. 15.
    Cesarman E, Chang Y, Moore PS, et al.: Kaposi’s sarcomaassociated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995, 332:1186–1191. First paper identifying the link between KSHV and primary effusion lymphomas (also called body cavity-based lymphomas).PubMedCrossRefGoogle Scholar
  16. 16.
    Soulier J, Grollet L, Oksenhendler E, et al.: Kaposi’s sarcomaassociated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 1995, 86:1276–1280. First paper identifying the link between KSHV and multicentric Castleman’s disease.PubMedGoogle Scholar
  17. 17.
    Parravicini C, Chandran B, Corbellino M, et al.: Differential viral protein expression in Kaposi’s sarcoma-associated herpesvirus-infected diseases: Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Am J Pathol 2000, 156:743–749.PubMedGoogle Scholar
  18. 18.
    Du MQ, Liu H, Diss TC, et al.: Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001, 97:2130–2136.PubMedCrossRefGoogle Scholar
  19. 19.
    Ablashi DV, Chatlynne LG, Whitman JE, Jr, et al.: Spectrum of Kaposi’s sarcoma-associated herpesvirus, or human herpesvirus 8 diseases. Clin Microbiol Rev 2002, 15:439–464.PubMedCrossRefGoogle Scholar
  20. 20.
    Nador RG, Cesarman E, Chadburn A, et al.: Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood 1996, 88:645–656.PubMedGoogle Scholar
  21. 21.
    Du MQ, Diss TC, Liu H, et al.: KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood 2002, 100:3415–3418.PubMedCrossRefGoogle Scholar
  22. 22.
    Deloose ST, Smit LA, Pals FT, et al.: High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia 2005, 19:851–855.PubMedCrossRefGoogle Scholar
  23. 23.
    Carbone A, Gloghini A, Vaccher E, et al.: Kaposi’s sarcomaassociated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma. J Mol Diagn 2005, 7:17–27.PubMedGoogle Scholar
  24. 24.
    Cool CD, Rai PR, Yeager ME, et al.: Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003, 349:1113–1122.PubMedCrossRefGoogle Scholar
  25. 25.
    Katano H, Ito K, Shibuya, K, et al.: Lack of human herpesvirus 8 infection in lungs of Japanese patients with primary pulmonary hypertension. J Infect Dis 2005, 191:743–745.PubMedCrossRefGoogle Scholar
  26. 26.
    Kedes DH, Operskalski E, Busch M, et al.: The seroepidemiology of human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med 1996, 2:918–924.PubMedCrossRefGoogle Scholar
  27. 27.
    Whitby D, Luppi M, Barozzi P, et al.: Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy. J Natl Cancer Inst 1998, 90:395–397.PubMedCrossRefGoogle Scholar
  28. 28.
    Damania B: Oncogenic gamma-herpesviruses: comparison of viral proteins involved in tumorigenesis. Nat Rev Microbiol 2004, 2:656–668.PubMedCrossRefGoogle Scholar
  29. 29.
    Russo JJ, Bohenzky RA, Chien MC, et al.: Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A 1996, 93:14862–14867. Sequence of the entire KSHV genome.PubMedCrossRefGoogle Scholar
  30. 30.
    Fakhari FD, Dittner DP: Charting latency transcripts in Kaposi’s sarcoma-associated herpesvirus by whole-genome real-time quantitative reverse transcription-PCR. J Virol 2002, 76:6213–6223.PubMedCrossRefGoogle Scholar
  31. 31.
    Dittmer DP: Transcription profile of Kaposi’s sarcomaassociated herpesvirus in primary Kaposi’s sarcoma lesions as determined by real-time PCR arrays. Cancer Res 2003, 63:2010–5.PubMedGoogle Scholar
  32. 32.
    Jenner RG, Alba MM, Boshoff C, et al.: Kaposi’s sarcomaassociated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J Virol 2001, 75:891–902.PubMedCrossRefGoogle Scholar
  33. 33.
    Lee H, Veazey R, Williams K, et al.: Deregulation of cell growth by the K1 gene of Kaposi’s sarcoma-associated herpesvirus. Nat Med 1998, 4:435–440.PubMedCrossRefGoogle Scholar
  34. 34.
    Lagunoff M, Majeti R, Weiss A, et al.: Deregulated signal transduction by the K1 gene product of Kaposi’s sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A 1999, 96:5704–5709.PubMedCrossRefGoogle Scholar
  35. 35.
    Lee H, Guo J, Li M, et al.: Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi’s sarcoma-associated herpesvirus. Mol Cell Biol 1998, 18:5219–5228.PubMedGoogle Scholar
  36. 36.
    Tomlinson CC, Damania B: The K1 protein of Kaposi’s sarcoma-associated herpesvirus activates the Akt signaling pathway. J Virol 2004, 78:1918–1927.PubMedCrossRefGoogle Scholar
  37. 37.
    Wang L, Wakisaka N, Tomlinson CC, et al.: The Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res 2004, 15:2774–2781.CrossRefGoogle Scholar
  38. 38.
    Prakash O, Tang ZY, Peng X, et al.: Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 k1 gene. J Natl Cancer Inst 2002, 94:926–935.PubMedGoogle Scholar
  39. 39.
    Samaniego F, Pati S, Karp J, et al.: Human herpesvirus 8 k1-associated nuclear factor-kappa b-dependent promoter activity: role in Kaposi’s sarcoma inflammation? J Natl Cancer Inst Monogr 2001, 28:15–23.PubMedGoogle Scholar
  40. 40.
    Bowser BS, DeWire SM, Damania B: Transcriptional regulation of the K1 gene product of Kaposi’s sarcoma-associated herpesvirus. J Virol 2002, 76:12574–12583.PubMedCrossRefGoogle Scholar
  41. 41.
    Lee BS, Connole M, Tang Z, et al.: Structural analysis of the Kaposi’s sarcoma-associated herpesvirus K1 protein. J Virol 2003, 77:8072–8086.PubMedCrossRefGoogle Scholar
  42. 42.
    Cesarman E, Nador RG, Bai F, et al.: Kaposi’s sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi’s sarcoma and malignant lymphoma. J Virol 1996, 70:8218–8223.PubMedGoogle Scholar
  43. 43.
    Chiou CJ, Poole LJ, Kim PS, et al.: Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi’s sarcomaassociated herpesvirus. J Virol 2002, 76:3421–3439.PubMedCrossRefGoogle Scholar
  44. 44.
    Arvanitakis L, Geras-Raaka E, Varma A, et al.: Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 1997, 385:347–350.PubMedCrossRefGoogle Scholar
  45. 45.
    Gershengorn MC, Geras-Raaka E, Varma A, et al.: Chemokines activate Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture. J Clin Invest 1998, 102:1469–1472.PubMedCrossRefGoogle Scholar
  46. 46.
    Geras-Raaka E, Varma A, Clark-Lewis I, et al.: Kaposi’s sarcoma-associated herpesvirus (KSHV) chemokine vMIP-II and human SDF-1alpha inhibit signaling by KSHV G protein-coupled receptor. Biochem Biophys Res Commun 1998, 253:725–727.PubMedCrossRefGoogle Scholar
  47. 47.
    Moore PS, Chang Y: Kaposi’s sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin? Annu Rev Microbiol 2003, 57:609–639.PubMedCrossRefGoogle Scholar
  48. 48.
    Bais C, Santomasso B, Coso O, et al.: G-protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998, 391:86–89.PubMedCrossRefGoogle Scholar
  49. 49.
    Bais C, Van Geelen A, Eroles P, et al.: Kaposi’s sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell 2003, 3:131–143.PubMedCrossRefGoogle Scholar
  50. 50.
    Montaner S, Sodhi A, Molinolo A, et al.: Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi’s sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003, 3:23–36.PubMedCrossRefGoogle Scholar
  51. 51.
    Sodhi A, Montaner S, Patel V, et al.: The Kaposi’s sarcomaassociated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 2000, 60:4873–4880.PubMedGoogle Scholar
  52. 52.
    Yang TY, Chen SC, Leach MW, et al.: Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi’s sarcoma. J Exp Med 2000, 191:445–454.PubMedCrossRefGoogle Scholar
  53. 53.
    Sadler R, Wu L, Forghani B, et al.: A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi’s sarcoma-associated herpesvirus. J Virol 1999, 73:5722–5730.PubMedGoogle Scholar
  54. 54.
    Muralidhar S, Pumfery AM, Hassani M, et al.: Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus) transforming gene. J Virol 1998, 72:4980–4988.PubMedGoogle Scholar
  55. 55.
    Kliche S, Nagel W, Kremmer E, et al.: Signaling by human herpesvirus 8 kaposin A through direct membrane recruitment of cytohesin-1. Mol Cell 2001, 7:833–843.PubMedCrossRefGoogle Scholar
  56. 56.
    McCormick C, Ganem D: The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 2005, 307:739–741.PubMedCrossRefGoogle Scholar
  57. 57.
    Staskus KA, Sun R, Miller G, et al.: Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. J Virol 1999, 73:4181–4187.PubMedGoogle Scholar
  58. 58.
    Dittmer D, Lagunoff M, Renne R, et al.: A cluster of latently expressed genes in Kaposi’s sarcoma-associated herpesvirus. J Virol 1998, 72:8309–8315.PubMedGoogle Scholar
  59. 59.
    Ballestas ME, Chatis PA, Kaye KM: Efficient persistence of extrachromosomal KSHV DNA mediated by latencyassociated nuclear antigen. Science 1999, 284:641–644.PubMedCrossRefGoogle Scholar
  60. 60.
    Cotter MA II, Subramanian C, Robertson ES: The Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen binds to specific sequences at the left end of the viral genome through its carboxy-terminus. Virology 2001, 291:241–259.PubMedCrossRefGoogle Scholar
  61. 61.
    Garber AC, Hu J, Renne R: LANA cooperatively binds to two sites within the terminal repeat, both sites contribute to lana’s ability to suppress transcription and facilitate DNA replication. J Biol Chem 2002, 277:27401–27411.PubMedCrossRefGoogle Scholar
  62. 62.
    Friborg J Jr, Kong W, Hottiger MO, et al.: p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999, 402:889–894.PubMedGoogle Scholar
  63. 63.
    Radkov SA, Kellam P, Boshoff C: The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000, 6:1121–1127.PubMedCrossRefGoogle Scholar
  64. 64.
    Watanabe T, Sugaya M, Atkins AM, et al.: Kaposi’s sarcomaassociated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. J Virol 2003, 77:6188–196.PubMedCrossRefGoogle Scholar
  65. 65.
    Fujimuro M, Hayward SD: The latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3beta. J Virol 2003, 77:8019–8030.PubMedCrossRefGoogle Scholar
  66. 66.
    Moore PS, Boshoff C, Weiss RA, et al.: Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996, 274:1739–1744.PubMedCrossRefGoogle Scholar
  67. 67.
    Nicholas J, Ruvolo VR, Burns WH, et al.: Kaposi’s sarcomaassociated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med 1997, 3:287–292.PubMedCrossRefGoogle Scholar
  68. 68.
    Chatterjee M, Osborne J, Bestetti G, et al.: Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science 2002, 298:1432–1435.PubMedCrossRefGoogle Scholar
  69. 69.
    Molden J, Chang Y, You Y, et al.: A Kaposi’s sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem 1997, 272:19625–19631.PubMedCrossRefGoogle Scholar
  70. 70.
    Boshoff C, Endo Y, Collins PD, et al.: Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 1997, 278:290–294.PubMedCrossRefGoogle Scholar
  71. 71.
    Sozzani S, Luini W, Bianchi G, et al.: The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood 1998, 92:4036–4039.PubMedGoogle Scholar
  72. 72.
    Stine JT, Wood C, Hill M, et al.: KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood 2000, 95:1151–1157.PubMedGoogle Scholar
  73. 73.
    Weber KS, Grone HJ, Rocken M, et al.: Selective recruitment of Th2-type cells and evasion from a cytotoxic immune response mediated by viral macrophage inhibitory protein-II. Eur J Immunol 2001, 31:2458–2466.PubMedCrossRefGoogle Scholar
  74. 74.
    Northfelt DW, Dezube BJ, Thommes JA, et al.: Pegylatedliposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998, 16:2445–2451.PubMedGoogle Scholar
  75. 75.
    Noy A, Scadden DT, Lee J, et al.: Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi’s sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol 2005, 23:990–998.PubMedCrossRefGoogle Scholar
  76. 76.
    Koon HB, Bubley GJ, Pantanowitz L, et al.: Imatinib-induced regression of AIDS-related Kaposi’s sarcoma. J Clin Oncol 2005, 23:982–989.PubMedCrossRefGoogle Scholar
  77. 77.
    Stallone G, Schena A, Infante B, et al.: Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 2005, 352:1317–1323.PubMedCrossRefGoogle Scholar
  78. 78.
    Clifford GM, Polesel J, Rickenbach M, et al.: Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005, 97:425–432.PubMedCrossRefGoogle Scholar
  79. 79.
    Cote TR, Biggar RJ, Rosenberg PS, et al.: Non-Hodgkin’s lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997, 73:645–650.PubMedCrossRefGoogle Scholar
  80. 80.
    Casper C, Nichols WG, Huang ML, et al.: Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004, 103:1632–1634.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Emily L. Wong
  • Blossom Damania
    • 1
  1. 1.Lineberger Comprehensive Cancer Center, CB #7295University of North CarolinaChapel HillUSA

Personalised recommendations